Leveraging our proprietary NanoPortal™ platform technology, we are developing a portfolio of miniature, long-term drug implants to address two main barriers of optimal chronic disease treatment: medication non-adherence and tolerability. Our lead assets, NPM-119 and NPM-115, are miniature, six-month, GLP-1 (exenatide) implants under development for type 2 diabetes and obesity, respectively.
We believe our growing portfolio could help patients live free from the administration hassles of daily or weekly medications. For physicians, caregivers and loved ones, this would mean greater confidence that patients are receiving their prescribed doses and potentially achieving better clinical outcomes.
NPM-119 is a pharmaceutical GLP-1 agonist (exenatide) implant under investigation for the treatment of patients with type 2 diabetes.
NPM-115 is a pharmaceutical GLP-1 agonist (high-dose exenatide) implant under investigation for the treatment of weight management in obese or overweight patients.
We strive to build the future of Vivani through both a strong capital base and the expertise of our entrepreneurial innovators. Our scientists and executives pool their collective knowledge in drug development, implant technology and chronic diseases to drive our pipeline forward.